Evusheld is indicated for the pre-exposure prophylaxis of COVID-19 in adults and adolescents aged 12 years and older weighing at least 40 kg.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||09/03/2022|
|Rapid review completed||11/04/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tixagevimab/cilgavimab compared with the current standard of care.|
|Full pharmacoeconomic assessment commissioned by the HSE||29/04/2022|
|Pre-submission consultation with Applicant||29/06/2022|
|Full HTA submission received from Applicant||16/08/2022|
|Preliminary review sent to Applicant||28/10/2022|
|NCPE assessment re-commenced||28/11/2022|
|Factual accuracy check sent to Applicant||12/12/2022|
|NCPE assessment re-commenced||19/12/2022|
|NCPE assessment completed||21/12/2022|
|NCPE assessment outcome||The NCPE recommends that tixagevimab/cilgavimab not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.